• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bisphosphonate treatment reduces breast cancer recurrence in the bones of post-menopausal women

byStefan Trela
July 27, 2015
in Chronic Disease, Obstetrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This meta-analysis showed that bisphosphonate treatment in women with breast cancer significantly reduced the risk of cancer recurrence in bone compared to placebo.

2. In post-menopausal women, bisphosphonate treatment significantly reduced the risk of breast cancer recurrence, distant cancer recurrence, cancer recurrence in bone, and breast cancer mortality, but did not significantly affect outcomes in pre-menopausal women.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Bisphosphonates are commonly used to treat osteoporosis, especially in post-menopausal women, as a way to reduce bone loss and fracture risk. Additionally, bisphosphonates can also be used to reduce the risk of fractures in metastatic cancers to bones. Previous studies using bisphosphonates for treatment of bone metastases in patients with breast cancer have shown mixed results. This meta-analysis of 18,766 women with breast cancer from 26 previous clinical trials attempted to determine whether bisphosphonates reduce the risk of bone metastases and whether menopausal status plays a role in treatment efficacy.

The results showed that bisphosphonates had a highly significant reduction in bone recurrence when compared to placebo, but had only borderline significance in the rate of cancer recurrence, distant recurrence, and breast cancer mortality. Additionally, bisphosphonate treatment in pre-menopausal women did not significantly affect outcomes, but significantly reduced recurrence, distant recurrence, bone recurrence, and breast cancer mortality in post-menopausal women. This study was strengthened by the analyses of specific subgroups within the sample population, but limited by the inability to assess the efficacy of the standard bisphosphonate treatments for osteoporosis as treatments for breast cancer.

Click to read the study in The Lancet

Relevant Reading: Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

RELATED REPORTS

Efanesoctocog alfa is efficacious in treating severe hemophilia A

Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

In-Depth [meta-analysis]: This meta-analysis included data from 18,766 (11,767 post-menopausal) women in 26 trials. Eligible trials included those that began before 2008 and randomized women to receive either a bisphosphonate or placebo. 18,706 participants (97%) received bisphosphonates for 2-5 years. The primary endpoints were any recurrence of breast cancer, distant recurrence, and breast cancer mortality.

Bisphosphonates did not significantly reduce the rate of cancer recurrence (Rate ratio [RR] 0.94, 95% Confidence Interval [CI] 0.87-1.01; 2p=0.08), but had a borderline statistically significant reduction in the risk of distant recurrence (0.92, 0.85-0.99; 2p=0.03) and breast cancer mortality (0.91, 0.83-0.99; 2p=0.04). However, bisphosphonates had a highly significant reduction in the rate of bone recurrence compared to placebo (10-year risk 7.8% vs. 9.0%; RR 0.83, 0.73-0.94; 2p=0.004). When analyzing for menopausal status, bisphosphonates did not significantly affect any of the primary outcomes in pre-menopausal women, but significantly reduced recurrence (RR 0.86, 95% CI 0.78-0.94; 2p=0.002), distant recurrence (0.82, 0.74-0.92; 2p=0.0003), bone recurrence (0.72, 0.60-0.86; 2p=0.0002), and breast cancer mortality (0.82, 0.73-0.93; 2p=0.002) in post-menopausal women. Additionally, bisphosphonates reduced the risk of bone fractures (RR 0.85, 95% CI 0.75-0.97; 2p=0.02).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Computer-extracted MRI features help distinguish benign from malignant prostate lesions

Next Post

Physician gaps in maternal infant care counseling

RelatedReports

Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial

February 2, 2023
CPAP may not decrease cardiovascular events in sleep apnea
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

February 2, 2023
Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest
Cardiology

Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival

February 2, 2023
Next Post
Physician gaps in maternal infant care counseling

Physician gaps in maternal infant care counseling

Validation of prediction tool for pediatric head trauma etiology

Validation of prediction tool for pediatric head trauma etiology

Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer

2 Minute Medicine Rewind July 20 – 26, 2015

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options